Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

Inclusion Criteria:

- COPD diagnosis as defined by the study physician

- Currently on one of the following maintenance therapies:

- LAMA monotherapy

- LABA monotherapy

- ICS/LABA (FDC)

- Physician determination that patient is not controlled on current pharmacotherapy

- Adult patient 40 years of age or older at time of study enrollment

- Willingness and ability to understand and provide documented Informed Consent Form
(ICF) and Health Insurance Portability and Accountability Act (HIPAA) Authorization
Form prior to commencement of any study required assessments, either directly or
through Legally Authorized Representative.

Exclusion Criteria:

- Currently on LAMA/LABA (free or FDC) or triple therapy (ICS plus LABA plus LAMA)

- Contraindication to any study medications (LAMA, LABA or ICS)

- Documented diagnosis of current asthma

- Pregnant or nursing women

- Women of childbearing potential are not restricted in this trial, however it is
expected that the investigator will assess the risks and benefits of the assigned
treatment as per the product label(s) and discuss this with any women of childbearing
potential prior to providing the patient with the prescription for the assigned
treatment.